Lipella Reports Successful Top Line Results in Phase 2a Study

Clinical-stage biotechnology company, Lipella Pharmaceuticals (LIPO) has released positive top line results from its Phase 2a clinical trial investigating a potential treatment for hemorrhagic cystitis.

The trial showed statistically significant safety and efficacy for Lipella’s drug candidate, LP-10. The company plans to communicate with the FDA on the study’s results and the pathway forward to seeking regulatory approval for LP-10.


  • The clinical trial was a multi-center, dose-escalation study of 13 subjects with moderate to severe refractory hemorrhagic cystitis.
  • All subjects tolerated LP-10 instillations and completed the study without report of product related serious adverse events.
  • This milestone positions Lipella to potentially provide a first-in-class treatment for the cancer survivor community living with hemorrhagic cystitis.
  • Hemorrhagic cystitis is a rare but highly morbid disease for which there are currently no FDA approved treatments.

Value Drivers

  • LP-10 peak annual revenue estimates in hemorrhagic cystitis exceed $1 billion.
  • Radiation results in hemorrhagic cystitis for approximately 60,000 patients each year.
  • LP-10 has been granted orphan drug designation by the FDA.
  • Lipella has patent protection for LP-10 through 2034.
  • Given the severity of hemorrhagic cystitis and the lack of adequate treatment, LP-10 will potentially be a candidate for multiple accelerated regulatory pathways.

Lipella is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Reports Successful Top Line Results in Phase 2a Study

Editor Prism MarketView